Navigation Links
Not in the mood but want to be? New studies bring women hope
Date:12/4/2013

CLEVELAND, Ohio (December 4, 2013)For women, passing midlife can deal a blow to their sex drive. But two new studies just published online in Menopause, the journal of The North American Menopause Society, offer hope to women who want to get their sexual mojo back.

No testosterone treatment for women has yet passed muster with the FDA. An important step toward developing a successful and safe treatment for women after natural or surgical menopause is to find out how much testosterone is really needed to bring desire back. One of these studies looked for that, as well as how much it took to produce other testosterone-related effects, such as increases in lean body mass, in women who had undergone hysterectomy. The other study tested a nonhormonal therapy, flibanserin, which did not meet FDA approval before but has since been resubmitted to the agency.

When FDA first reviewed flibanserin for this purpose in 2010, the agency did not think it made a difference that was meaningfully different from placebo. This new study in women who had very low desire and were distressed about it showed some statistically significant differences. The women who took flibanserin (100 mg/day at bedtime) had increases in the number of satisfying sexual encounters (SSEs) and in a standard score of desire that were statistically better than placebo. Thirty percent of the women experienced side effects, including dizziness, sleepiness, nausea, and headache, but only 8% stopped taking the drug because of them.

The testosterone study included women ages 21 to 60 who had undergone hysterectomy. They all had testosterone levels that were lower than the average for healthy young women. Because the ovary continues to secrete male hormones after menopause, there is usually little decrease in testosterone levels for women who go through menopause naturally, but in women who undergo any type of hysterectomy, testosterone levels drop substantially. Women who also have one or both ovaries removed, even if they take estrogen, have worse sexual function than women who still have one or both ovaries. All the women took estrogen and then also got injections of placebo or of different doses of testosterone enanthate for six months.

Only the women who got the highest dose25-mg weeklyhad statistically significant improvements in their libido and other measures of sexual function as well as in lean body mass and muscle strength. That dose raised testosterone levels to about 210 ng/dL, which is nearly five to six times higher than a healthy, normal level. So simply raising low testosterone levels to what's normal won't improve sexual function and these other measures, concluded the investigators. But is it a dangerous level?

The investigators saw no serious adverse effects. Total and LDL cholesterol, triglycerides, and fasting glucose didn't change significantly in the women who got testosterone. Levels of HDL, the "good cholesterol," did decrease, but not in a statistically significant way. Nevertheless, cautioned the authors, the cardiovascular and metabolic risks need to be investigated in long-term trials.

"Keeping hormone levels within the normal range for your gender and age is the safest approach. Hormones affect many systems in the body, and it takes a large and long-term study to identify side effects. One recent well-designed study in men reported that mortality was greater among older men taking testosterone. More is not necessarily better when it comes to hormones," says The North American Menopause Society Executive Director Margery Gass, MD.


'/>"/>

Contact: Eileen Petridis
epetridis@fallscommunications.com
216-696-0229
The North American Menopause Society (NAMS)
Source:Eurekalert

Related medicine news :

1. End-Year Special Offer on Research Studies by Current Partnering Now Available at MarketPublishers.com
2. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Johnson & Johnson Bid to Keep Clinical Studies Under Seal
3. The importance of standardizing drug screening studies
4. Diet Doc Hormone Diets & Weight Loss Plans Announces New Diet Plans Helping Women Lose Excess Fat Prior to Pregnancy, Which Studies Show Leads to Fewer Complications
5. Contract Research Organization WCCT Global Announces Clinical Trial Patient Recruitment Services for International Clinical Studies
6. Studies Show Stand Up Desks Spur Productivity & Creativity
7. Study Funded by National Foundation for Cancer Research Reveals Imaging Studies May Predict Tumor Response to Anti-Angiogenic Drugs
8. New case studies link smoking synthetic marijuana with stroke in healthy, young adults
9. Studies explore potential origins of addiction and treaments
10. Studies explore potential origins of addiction and treatments
11. Studies pinpoint specific brain areas and mechanisms associated with depression and anxiety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... For Immediate Release, Contact: ... leading provider of innovative software for connected home healthcare, today announced Orbita ... journey management for home healthcare. , Built on Orbita Health Cloud ...
(Date:2/20/2017)... , ... February 20, 2017 , ... The StayWell ... help health care providers better manage patient health risks, foster behavior change and improve ... library in the world, will present a demonstration of its video capability at StayWell ...
(Date:2/20/2017)... ... 2017 , ... Best Doctors® and IBM today announced that ... that want to help members of their workforce battling cancer. Through the Best ... suite of oncology offerings for insights on cancer treatment options, ranging from standard ...
(Date:2/20/2017)... ... 2017 , ... Johns Hopkins All Children's Hospital celebrated a major milestone with ... Friday marked the halfway point of construction and lifting of the final beam on ... as a center for innovation aimed at finding new discoveries and treatments for childhood ...
(Date:2/20/2017)... ... February 20, 2017 , ... Florida Hospital Pepin Heart ... ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks up life-threatening blood clots by ... Family Foundation. , “We greatly appreciate this gift from Constellation Brands. We are ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... 21, 2017 Cognitive Computing for Cancer ... allowing a previously unattainable level of personalized treatment ... ability, it is anticipated that the Global Cancer ... by 2022. The growth of the market is ... platforms, rising installation of cognitive computing software in ...
(Date:2/21/2017)... 2017 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the ... company will release its fourth quarter and full year ... February 28, 2017. The press release will be followed ... will be open to the public via telephone and ... its financial results and provide a business update. ...
(Date:2/21/2017)... Feb. 21, 2017  International Isotopes Inc. (OTCQB: INIS) ... placement with certain investors for approximately $3.4 million of ... Series C Convertible Redeemable Preferred Stock (the "Series C ... annual rate of 6% and is convertible into common ... use the proceeds for operating capital, to pay off ...
Breaking Medicine Technology: